PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
A number of groups have demonstrated very low incidence of acute and chronic
graft-versus-host disease (GVHD) with post-transplantation cyclophosphamide (PTCy) in
haploidentical and unrelated allogeneic stem cell transplantation (SCT). Still the relapse of
the underlining malignancy is a problem after this prophylaxis. Ruxolitinib is currently one
of the most promising drugs in the treatment of steroid-refractory GVHD. On the other hand,
its primary indication is myelofibrosis, and it was demonstrated that ruxolitinib before
allogeneic SCT might improve the outcome. This pilot trial evaluates whether the combination
of PTCy and ruxolitinib facilitates adequate GVHD control, and decreases the risk of graft
failure and disease progression in myelofibrosis patients.